A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...

Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its ...

Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19.

A final analysis confirmed that Pfizer’s investigational oral antiviral, Paxlovid, reduced the risk for severe COVID-19 outcomes by almost 90% when given within days of symptom onset, as first ...

However, the efficacy estimates of the COVID-19 vaccines from the trials mentioned above were much higher than the FDA and WHO threshold. In all the different trials, different factors have been ...

The updated trial analysis (ClinicalTrials.gov Identifier: NCT04575597) included 1433 adults with mild to moderate COVID-19 with symptom onset within 5 days of randomization.

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

Since appearing in late 2019, the SARS-CoV-2 virus has caused sickness and death across the globe. Researchers and scientists have been looking at multiple solutions to treat COVID-19, including ...